Epidermal growth factor receptor variant Ⅲ (EGFRvⅢ) is a constitutively-activated mutation of EGFR that contributes to the malignant progression of glioblastoma multiforme (GBM). Temozolomide (TMZ) is a standard chemotherapeutic for GBM, but TMZ treatment benefits are compromised by chemoresistance. This study aimed to elucidate the crucial mechanisms leading to EGFRvⅢ and TMZ resistance.
CRISPR-Cas13a single-cell RNA-seq was performed to thoroughly mine EGFRvⅢ function in GBM. Western blot, realtime PCR, flow cytometry, and immunofluorescence were used to determine the chemoresistance role of E2F1 and RAD51-associated protein 1(RAD51AP1).
Bioinformatic analysis identified E2F1 as the key transcription factor in EGFRvⅢ-positive living cells. Bulk RNA-seq analysis revealed that E2F1 is a crucial transcription factor under TMZ treatment. Western blot suggested enhanced expression of E2F1 in EGFRvⅢ-positive and TMZ-treated glioma cells. Knockdown of E2F1 increased sensitivity to TMZ. Venn diagram profiling showed that RAD51AP1 is positively correlated with E2F1, mediates TMZ resistance, and has a potential E2F1 binding site on the promoter. Knockdown of RAD51AP1 enhanced the sensitivity of TMZ; however, overexpression of RAD51AP1 was not sufficient to cause chemotherapy resistance in glioma cells. Furthermore, RAD51AP1 did not impact TMZ sensitivity in GBM cells with high O6-methylguanine-DNA methyltransferase (MGMT) expression. The level of RAD51AP1 expression correlated with the survival rate in MGMT-methylated, but not MGMT-unmethylated TMZ-treated GBM patients.
Our results suggest that E2F1 is a key transcription factor in EGFRvⅢ-positive glioma cells and quickly responds to TMZ treatment. RAD51AP1 was shown to be upregulated by E2F1 for DNA double strand break repair. Targeting RAD51AP1 could facilitate achieving an ideal therapeutic effect in MGMT-methylated GBM cells.
Maomao C, He L, Dianqin S, Siyi H, Xinxin Y, Fan Y, et al. Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med. 2022; 19: 1121-38.
Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018; 392: 432-46.
Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017; 35: 2402-9.
Zhang K, Liu X, Li G, Chang X, Li S, Chen J, et al. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA. Cancer Biol Med. 2022; 19: 1460-76.
Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022; 32: e13062.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.
Liu Y, Chen H, Li G, Zhang J, Yao K, Wu C, et al. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas. Cancer Biol Med. 2022; 19: 1477-86.
Moody CL, Wheelhouse RT. The medicinal chemistry of imidazotetrazine prodrugs. Pharmaceuticals (Basel). 2014; 7: 797-838.
Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021; 1876: 188616.
Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013; 332: 237-48.
Sun X, Turcan S. From laboratory studies to clinical trials: temozolomide use in IDH-mutant gliomas. Cells. 2021; 10: 1225.
Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT Status as a Clinical Biomarker in Glioblastoma. Trends Cancer. 2020; 6: 380-91.
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing--the challenges for biomarkerbased glioma treatment. Nat Rev Neurol. 2014; 10: 372-85.
Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019; 21: 167-78.
Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, et al. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021; 18: 272-82.
Chai RC, Liu YQ, Zhang KN, Wu F, Zhao Z, Wang KY, et al. A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Mod Pathol. 2019; 32: 4-15.
Lang F, Liu Y, Chou FJ, Yang C. Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 2021; 228: 107922.
Zhang X, Li T, Yang M, Du Q, Wang R, Fu B, et al. Acquired temozolomide resistance in MGMT(low) gliomas is associated with regulation of homologous recombination repair by ROCK2. Cell Death Dis. 2022; 13: 138.
Xu H, Jin J, Chen Y, Wu G, Zhu H, Wang Q, et al. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNAdamage repair. Oncogene. 2022; 41: 3876-85.
Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013; 4: e876.
Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001; 61: 1957-63.
Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019; 19: 326-38.
Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, et al. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res. 2007; 13: 144-51.
Chen J, Zhu F, Weaks RL, Biswas AK, Guo R, Li Y, et al. E2F1 promotes the recruitment of DNA repair factors to sites of DNAdouble-strand breaks. Cell Cycle. 2011; 10: 1287-94.
Guo R, Chen J, Mitchell DL, Johnson DG. GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res. 2011; 39: 1390-7.
Su SG, Li QL, Zhang MF, Zhang PW, Shen H, Zhang CZ. An E2F1/DDX11/EZH2 positive feedback loop promotes cell proliferation in hepatocellular carcinoma. Front Oncol. 2020; 10: 593293.
Ma J, He Z, Zhang H, Zhang W, Gao S, Ni X. SEC61G promotes breast cancer development and metastasis via modulating glycolysis and is transcriptionally regulated by E2F1. Cell Death Dis. 2021; 12: 550.
Chen S, He Z, Peng T, Zhou F, Wang G, Qian K, et al. PRR11 promotes cc RCC tumorigenesis by regulating E2F1 stability. JCIInsight. 2021; 6: e145172.
Rahme GJ, Zhang Z, Young AL, Cheng C, Bivona EJ, Fiering SN, et al. PDGF Engages an E2F-USP1 signaling pathway to support ID2-mediated survival of proneural glioma cells. Cancer Res. 2016; 76: 2964-76.
Kovalenko OV, Golub EI, Bray-Ward P, Ward DC, Radding CM. Anovel nucleic acid-binding protein that interacts with human rad51 recombinase. Nucleic Acids Res. 1997; 25: 4946-53.
Wang Q, Tan Y, Fang C, Zhou J, Wang Y, Zhao K, et al. Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvⅢ in human glioblastomas. Aging (Albany NY). 2019; 11(18): 7707-22.
Wang Q, Cai J, Fang C, Yang C, Zhou J, Tan Y, et al. Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-beta pathway. Theranostics. 2018; 8: 4733-49.
Yang C, Wang L, Sun J, Zhou JH, Tan YL, Wang YF, et al. Identification of long non-coding RNA HERC2P2 as a tumor suppressor in glioma. Carcinogenesis. 2019; 40: 956-64.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101-8.
Yang S, Zhao J, Cui X, Zhan Q, Yi K, Wang Q, et al. TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma. Theranostics. 2022; 12: 7032-50.
Wang Q, Liu X, Zhou J, Yang C, Wang G, Tan Y, et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv Sci (Weinh). 2019; 6: 1901299.
Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009; 21: 871-7.
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10: 1523.
Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, et al. Genome-wide CRISPR-Cas9 screening identifies NF-kappa B/E2F6 responsible for EGFRvⅢ-associated temozolomide resistance in glioblastoma. Adv Sci (Weinh). 2019; 6: 1900782.
Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteomics Bioinformatics. 2021; 19: 1-12.
Martin K, Trouche D, Hagemeier C, Kouzarides T. Regulation of transcription by E2F1/DP1. J Cell Sci Suppl. 1995; 19: 91-4.
Meng X, Zhao Y, Han B, Zha C, Zhang Y, Li Z, et al. Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and METsignaling pathways. Nat Commun. 2020; 11: 594.
Liang F, Longerich S, Miller AS, Tang C, Buzovetsky O, Xiong Y, et al. Promotion of RAD51-mediated homologous DNA pairing by the RAD51AP1-UAF1 complex. Cell Rep. 2016; 15: 2118-26.
Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021; 23: 920-31.
Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol. 2003; 5: 401-9.
Creative Commons Attribution-NonCommercial 4.0 International License